Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adagene Raises $69 Million in D Round for Novel Immunotherapies

publication date: Jan 9, 2020

Adagene, a Suzhou immunotherapy company, raised $69 million in a Series D financing, including $50 million from lead investor General Atlantic. The company combines computational biology and AI to design novel antibodies. It believes its platform offers new druggable targets and greater binding precision, resulting in a pipeline of novel immunotherapy programs with first or best in class potential. Adagene's lead molecule, ADG106, is an anti-CD137 monoclonal IgG4 antibody being tested in Phase I trials in solid and liquid cancers. Since 2014, Adagene has raised more than $150 million in venture capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital